HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea

被引：0
|
作者：
Peter N. Weissman
Molly C. Carr
June Ye
Deborah T. Cirkel
Murray Stewart
Caroline Perry
Richard Pratley
机构：
[1] Endocrinology Associates,Florida Hospital Diabetes Institute, Translational Research Institute for Metabolism and Diabetes
[2] GlaxoSmithKline,undefined
[3] GlaxoSmithKline,undefined
[4] Sanford-Burnham Medical Research,undefined
来源：
Diabetologia | 2014年 / 57卷
关键词：
Albiglutide; GLP-1 agonist; Insulin glargine; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2475 / 2484
页数：9
相关论文
共 50 条
  • [1] HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea
    Weissman, Peter N.
    Carr, Molly C.
    Ye, June
    Cirkel, Deborah T.
    Stewart, Murray
    Perry, Caroline
    Pratley, Richard
    [J]. DIABETOLOGIA, 2014, 57 (12) : 2475 - 2484
  • [2] Efficacy and safety of once-weekly dulaglutide versus insulin glargine in combination with metformin and/or sulfonylurea in Chinese patients with type 2 diabetes
    Wang, Weiqing
    Li, Pengfei
    Gu, Liqun
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2017, 33
  • [3] HARMONY 2 results at week 52 primary endpoint: once-weekly albiglutide monotherapy for patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
    Reinhardt, R.
    Nauck, M. A.
    Stewart, M.
    Perkins, C.
    Jones-Leone, A.
    Yang, F.
    Perry, C.
    Rendell, M.
    [J]. DIABETOLOGIA, 2013, 56 : S360 - S360
  • [4] Efficacy and Safety of Once-Weekly Dulaglutide vs. Insulin Glargine in Combination with Metformin and/or a Sulfonylurea in Predominantly Asian Patients with Type 2 Diabetes
    Wang, Weiqing
    Ruiz, Luis Nevarez
    Filippova, Ekaterina
    Song, Ki-Ho
    Gu, Liqun
    Li, Pengfei
    Yang, Jun
    [J]. DIABETES, 2015, 64 : A74 - A74
  • [5] HARMONY 1 results at week 52 primary endpoint: once-weekly albiglutide vs placebo in patients with type 2 diabetes mellitus not controlled on pioglitazone ± metformin
    Reusch, J.
    Stewart, M.
    Perkins, C.
    Ordronneau, P.
    Ye, J.
    Perry, C.
    Reinhardt, R.
    Bode, B.
    [J]. DIABETOLOGIA, 2013, 56 : S359 - S360
  • [6] Efficacy of dapagliflozin plus saxagliptin vs insulin glargine at 52 weeks in patients with type 2 diabetes inadequately controlled by metformin with or without sulfonylurea
    Vilsboll, T.
    Ekholm, E.
    Johnsson, E.
    Garcia-Sanchez, R.
    Dronamraju, N.
    Jabbour, S. A.
    Lind, M.
    [J]. DIABETOLOGIA, 2018, 61 : S380 - S380
  • [7] Once-weekly exenatide vs once- or twice-daily insulin detemir: randomised, open-label clinical trial of efficacy and safety in patients with Type 2 diabetes inadequately controlled with metformin alone or with sulphonylureas
    Davies, M.
    Heller, S.
    Sreenan, S.
    Sapin, H.
    Adetunji, O.
    Tahbaz, A.
    Vora, J.
    [J]. DIABETIC MEDICINE, 2013, 30 : 57 - 58
  • [8] A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy
    Shankar, R. Ravi
    Inzucchi, Silvio E.
    Scarabello, Victoria
    Gantz, Ira
    Kaufman, Keith D.
    Lai, Eseng
    Ceesay, Paulette
    Suryawanshi, Shailaja
    Engel, Samuel S.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (10) : 1853 - 1860
  • [9] Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial
    Bajaj, Harpreet S.
    Bergenstal, Richard M.
    Christoffersen, Andreas
    Davies, Melanie J.
    Gowda, Amoolya
    Isendahl, Joakim
    Lingvay, Ildiko
    Senior, Peter A.
    Silver, Robert J.
    Trevisan, Roberto
    Rosenstock, Julio
    [J]. DIABETES CARE, 2021, 44 (07) : 1586 - 1594
  • [10] Insulin glargine improves health related quality of life in patients with type 2 diabetes inadequately controlled on sulfonylurea plus metformin
    Vinik, AI
    Dailey, G
    Zhang, Q
    [J]. DIABETOLOGIA, 2005, 48 : A312 - A312
12345